These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33982209)

  • 21. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
    Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
    Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study.
    Martínez M; Jiménez S; Guzmán F; Fernández M; Arizaga E; Sanz C
    Breast J; 2022; 2022():6111907. PubMed ID: 35855102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
    Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
    Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
    de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
    Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of clipped node improve our results?
    Alarcón M; Buch E; Julve A; Hernandorena M; Tajahuerce M; Rodríguez H; Bermejo B; Ramírez J; Burgués O; Díaz S; Alcalá GM; Ortega J
    Surgeon; 2021 Dec; 19(6):344-350. PubMed ID: 33663946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
    Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
    Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Normalization in axillary lymph node management after neoadjuvant therapy for breast cancer].
    Wu D; Liu SY; Amina M; Fan ZM
    Zhonghua Wai Ke Za Zhi; 2019 Feb; 57(2):97-101. PubMed ID: 30704211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
    Baker JL; Haji F; Kusske AM; Fischer CP; Hoyt AC; Thompson CK; Lee MK; Attai D; DiNome ML
    Breast Cancer Res Treat; 2022 Jan; 191(1):107-114. PubMed ID: 34652548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted axillary dissection using Radioguided Occult Lesion Localization technique in the clinically negative marked lymph node after neoadjuvant treatment in breast cancer patients.
    Del Castillo A; Gomez-Modet S; Mata JM; Tejedor L
    Eur J Surg Oncol; 2023 Jul; 49(7):1184-1188. PubMed ID: 36958951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.
    El Hage Chehade H; Headon H; El Tokhy O; Heeney J; Kasem A; Mokbel K
    Am J Surg; 2016 Nov; 212(5):969-981. PubMed ID: 27671032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients.
    Acea-Nebril B; García-Novoa A; Bouzón Alejandro A; Díaz Carballada C; Conde Iglesias C
    Breast; 2023 Dec; 72():103592. PubMed ID: 37857128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
    Simons JM; van Nijnatten TJA; van der Pol CC; Luiten EJT; Koppert LB; Smidt ML
    Ann Surg; 2019 Mar; 269(3):432-442. PubMed ID: 30312200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry.
    Loveland-Jones C; Gaughan J; Caudle A; Murphy B; Samiian L; Byrum S; Brill K; Germaine P; Zhang X; Yoon-Flannery K; Carter T; Lopez A; Gruner R; Fantazzio M; Kuerer H
    Eur J Surg Oncol; 2024 Apr; 50(4):108245. PubMed ID: 38484493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wire guided localisation for targeted axillary node dissection is accurate in axillary staging in node positive breast cancer following neoadjuvant chemotherapy.
    Balasubramanian R; Morgan C; Shaari E; Kovacs T; Pinder SE; Hamed H; Sever AR; Kothari A
    Eur J Surg Oncol; 2020 Jun; 46(6):1028-1033. PubMed ID: 31879050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermediary clip placement to assist accurate axillary lymph node localization.
    Price ER; Vyas S; Lee AY; Wong JM; Joe BN; Ray KM
    Clin Imaging; 2021 May; 73():96-100. PubMed ID: 33352497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted axillary dissection using carbon marking for patients with node-positive breast cancer following neoadjuvant therapy (TADCOM): study protocol for a prospective, multicenter, randomized controlled trial.
    Chen W; Pang L; Jin X; Chen H; Huang J
    BMC Cancer; 2024 Oct; 24(1):1276. PubMed ID: 39402559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of the Axilla After Neoadjuvant Chemotherapy: Can Axillary Needle Biopsy Replace Sentinel Node Biopsy?
    Yildirim E; Basim P; Ucar N; Bektas S; Iscen K; Karci E; Ozdemir AA
    In Vivo; 2024; 38(5):2523-2530. PubMed ID: 39187354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
    Pinto CS; Peleteiro B; Pinto CA; Osório F; Costa S; Magalhães A; Mora H; Amaral J; Gonçalves D; Fougo JL
    Breast Cancer; 2022 Jul; 29(4):709-719. PubMed ID: 35304711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.